BMRN BIOMARIN PHARMACEUTICAL INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1048477 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY18.1%
TTM net income YoY-103.7%
TTM EPS YoY-103.7%
Revenue 3-yr CAGR16.5%
Net income 3-yr CAGR—
Margins
Gross margin76.0%
Operating margin3.1%
Net margin-0.5%
FCF margin15.3%
EBITDA margin4.7%
Returns
ROE-0.3%
ROA-0.2%
ROIC (approx.)0.8%
Asset turnover0.38x
Leverage & solvency
Liabilities / assets45.9%
Debt / equity0.67x
Current ratio2.44x
Interest coverage0.89x
Cash quality & payout
Operating cash flow / net income-35.40x
Accruals ratio-7.3%
Payout ratio—
Capex / revenue3.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.22B | $2.85B |
| Cost of revenue | $717.44M | $580.24M |
| Gross profit | $2.50B | $2.27B |
| R&D expense | $921.93M | $747.18M |
| SG&A expense | $1.15B | $1.01B |
| Operating income | $409.48M | $484.21M |
| Interest expense | $10.90M | $12.67M |
| Pretax income | $482.48M | $541.76M |
| Income tax | $133.58M | $114.90M |
| Net income | $348.90M | $426.86M |
| EBITDA | $489.04M | $580.64M |
| EPS (basic) | 1.82 | 2.25 |
| EPS (diluted) | 1.80 | 2.21 |
| Weighted avg. shares (diluted) | 197.39M | 196.71M |
| Balance sheet | ||
| Cash & equivalents | $1.31B | $942.84M |
| Short-term investments | $248.93M | $194.86M |
| Receivables | $908.21M | $660.53M |
| Inventory | $1.30B | $1.23B |
| Current assets | $3.95B | $3.23B |
| PP&E, net | $952.51M | $1.04B |
| Goodwill | $196.20M | $196.20M |
| Intangibles | $213.84M | $255.28M |
| Total assets | $7.59B | $6.99B |
| Current liabilities | $759.03M | $606.99M |
| Short-term debt | $0 | — |
| Long-term debt | $597.18M | — |
| Total debt | $597.18M | — |
| Total liabilities | $1.51B | $1.33B |
| Shareholders' equity | $6.09B | $5.66B |
| Net debt | -$714.50M | — |
| Shares outstanding | 192.30M | 190.76M |
| Cash flow statement | ||
| Operating cash flow | $827.99M | $572.84M |
| Capital expenditure | $103.04M | $85.42M |
| Free cash flow | $724.96M | $487.42M |
| Investing cash flow | -$414.24M | $136.49M |
| Financing cash flow | -$42.39M | -$526.45M |
| Depreciation & amortization | $79.56M | $96.43M |
| Stock-based compensation | $181.41M | $201.57M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.